A paediatric patient was treated with orthotopic liver transplantation after he developed cirrhosis of the liver due to chronic graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation. His preexisting chronic GVHD of the skin disappeared and immunosuppressive therapy could be gradually tapered and finally withdrawn 71 months after liver transplantation. Two and a half years after discontinuation of all immunosuppressive therapy, the patient is in excellent condition with neither signs of chronic GVHD nor rejection of the liver graft.
but severe anaemia with a haemoglobin level of 5.6 g/dl, haematocrit 25% and reduced MCV of 71.3 fl.
Sideroblastic anaemia was diagnosed on bone marrow aspiration and biopsy. Treatment with pyridoxine failed, and the patient repeatedly received blood transfusions. Subsequently, he developed secondary haemosiderosis, which was treated by administration of desferrioxamine for 14 months. Meanwhile, an HLA-identical female cousin was identified (patient: HLA: A 2,33 B 7,14 Cw Ϫ,Ϫ DR 2,3, female cousin: HLA: A 2,33, B 7,14 Cw 7,Ϫ DR 2,3). In July 1989 an allogeneic BMT was performed with 21ϫ10 8 nucleated cells/kg body weight. 1 Conditioning consisted of busulphan at a dose of 4 mg/kg/p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 50 mg/kg once daily i.v. for 4 days (total dose 200 mg/kg). GVHD prophylaxis consisted of cyclosporine and prednisone. After rapid engraftment, the patient developed an erythematous rash on day +27, diarrhoea and hepatomegaly accompanied by elevated liver enzymes. These findings were indicative of acute GVHD and led to intensified immunosuppressive therapy (Figure 1 ). Whereas the gut GVHD improved, GVHD of the skin and liver persisted which was later confirmed as chronic GVHD on liver and skin biopsy. His course was further complicated by chronic EBV infection in 1990. Finally, cirrhosis of the liver was diagnosed in April 1994. At that time, liver function tests showed AST 45 U/l, ALT 30 U/l, GGT 69 U/l, cholinesterase 832 U/l, alkaline phosphatase 233 U/l, total protein 4,5 g/dl, total bilirubin 21 mg/dl, prothrombin time 42%, partial thromboplastin time 63 s, thrombin time 18.4 s and fibrinogen 208 mg/dl. Subsequent rapid deterioration with liver failure, bleeding-coagulopathy, ascites and hyperammonaemia prompted an orthotopic liver transplant from a cadaveric donor HLA: A1,29 (19) , B 44(12),60,(40), DR 7,Ϫ in May 1994. Post-transplant immunosuppressive treatment consisted of cyclosporine, prednisone and azathioprine. The post-operative course was uncomplicated with normal liver function and rapid normalisation of serum bilirubin levels as well as liver enzymes. No clinical or laboratory signs of liver graft rejection or GVHD were seen, and the pre-existing GVHD of the skin gradually disappeared.
Treatment with prednisone was terminated after 6 months, and azathioprine was discontinued after 24 months. Since there were no signs of rejection, cyclosporine was tapered under close observation and finally discontinued after 71 months (Figure 1 ). Two and a half years after complete withdrawal of immunosuppressive therapy, the patient is in excellent condition without signs of GVHD and with stable liver graft function.
Discussion
Liver failure in our patient was caused by chronic GVHD which was confirmed by histological examination of the excised liver. Other factors such as haemosiderosis, EBV infection and drug toxicity may also have contributed to the progression of liver dysfunction making organ replacement necessary. Few patients have been reported to date who have had a LTx after BMT due to severe liver dysfunction. In these patients, liver failure was induced by GVHD or venoocclusive disease. [2] [3] [4] [5] [6] [7] [8] [9] To our knowledge, this is the first report in a paediatric patient describing cadaveric LTx after family donor BMT with the development of stable graft tolerance after complete withdrawal of immunosuppressive prophylaxis.
The mechanisms of tolerance induction in liver transplantation are not entirely clear, but development of microchimerism appears to play an important role. Starzl and colleagues [10] [11] [12] suggest that cell migration from the grafted liver may lead to a state of haematolymphopoietic chimerism, which has an immunomodulatory effect. These grafted cells are mainly lymphoid and dendritic cells (ie passenger-leukocytes), which migrate preferentially into the recipient's lymphoid organs. Normally, bone marrow derived donor cells such as Kupffer cells, are gradually replaced by similar cells of the recipient. Hence, post allogeneic bone marrow transplantation, when host haematopoietic cells become of donor origin, hepatic reticuloendothelial cells derived from an unrelated and mismatched donor are also likely to be replaced with donor cells. In this way, mixed chimerism in the liver could lead to diminished antigenicity, which is mostly expressed by bone marrowderived cells, thus explaining a decline of the immunogenicity of the allograft. [10] [11] [12] These phenomena are associated with allograft tolerance. Interestingly, the present case demonstrates that allogeneic lymphocytes can be tolerized to all alloantigens expressed in the new milieu, host's and even new additional antigens expressed by the unrelated liver allograft. The haematolymphopoietic chimerism in some organ recipients may explain why weaning to a drugfree state in selected long-term survivors is feasible, particularly if the allograft is liver-derived. Discontinuance of immunosuppression after LTx was shown in six out of 44 long-term survivors. 13 Drug-free tolerance in other organ transplantations and even tolerance to the most immunogenic skin was only achieved by full chimerism in cases when bone marrow and organ transplant were of the same donor, ie in some kidney transplantations and in a patient with transplantation of a lobe of the lung [14] [15] [16] [17] or with donor skin. 18 Recently, full donor chimerism with tolerance was described in a patient after living related liver transplantation followed by haploidentical stem cell transplantation from the same donor. 19 Clinical trials to enhance chimerism after solid organ transplantation by perioperative infusion of donor-derived bone marrow cells are currently explored. The goal is to facilitate long-term allograft survival and function, and to achieve a drug-free state in selected patients. [20] [21] [22] Another promising approach to prepare recipients for organ allografting could be the establishment of mixed chimerism through well-tolerated non-myeloablative stem cell transplantation. 23 The case of our patient confirms other reports that LTx is a feasible therapy for end-stage liver-GVHD after BMT, even in paediatric patients. It can be hypothesized that the liver graft in our patient may have altered the immunological state with development of bidirectional tolerance as shown by the disappearence of pre-existing skin GVHD on the one hand and stable graft function without further immunosuppressive therapy on the other.
The immunological mechanism in operation in our patient still remains obscure, but understanding it may also be of importance in attainment of a drug-free status in other organ transplant recipients.
